Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement

Affiliations

¹ Department of Pediatrics, Divisions of Pediatric Infectious Diseases & Clinical Pharmacology, Children's Mercy Hospitals & Clinic, 2401 Gillham Rd., Kansas City, MO, 64108, USA. jlgoldman@cmh.edu.
² Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung and Linkou Branches, College of Medicine, Chang Gung University, Taipei, Taiwan.
³ Division of Health Services and Outcomes Research, Children's Mercy Hospitals & Clinics, Kansas City, USA.
⁴ Department of Dermatology, University Hospital Linz, Linz, Austria.
⁵ Department of Dermatology, University of Pennsylvania, Philadelphia, USA.
⁶ Food and Drug Administration, Silver Spring, USA.
⁷ Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, USA.
⁸ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center and University of Toronto, Toronto, Canada.
⁹ Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA.
¹⁰ Department ofMolecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Published Erratum

Jennifer L Goldman et al. Eur J Clin Pharmacol. 2019 Sep.

. 2019 Sep;75(9):1331.

doi: 10.1007/s00228-019-02710-4.

¹ Department of Pediatrics, Divisions of Pediatric Infectious Diseases & Clinical Pharmacology, Children's Mercy Hospitals & Clinic, 2401 Gillham Rd., Kansas City, MO, 64108, USA. jlgoldman@cmh.edu.
² Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Keelung and Linkou Branches, College of Medicine, Chang Gung University, Taipei, Taiwan.
³ Division of Health Services and Outcomes Research, Children's Mercy Hospitals & Clinics, Kansas City, USA.
⁴ Department of Dermatology, University Hospital Linz, Linz, Austria.
⁵ Department of Dermatology, University of Pennsylvania, Philadelphia, USA.
⁶ Food and Drug Administration, Silver Spring, USA.
⁷ Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, USA.
⁸ Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center and University of Toronto, Toronto, Canada.
⁹ Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA.
¹⁰ Department ofMolecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

Abstract

The correct name of the 9th Author is David J. Margolis. The original article was corrected.

Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.
Goldman JL, Chung WH, Lee BR, Chen CB, Lu CW, Hoetzenecker W, Micheletti R, Yasuda SU, Margolis DJ, Shear NH, Struewing JP, Pirmohamed M. Goldman JL, et al. Eur J Clin Pharmacol. 2019 Aug;75(8):1135-1141. doi: 10.1007/s00228-019-02670-9. Epub 2019 Mar 27. Eur J Clin Pharmacol. 2019. PMID: 30918988 Free PMC article.